

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes
Thomas Pap
David Pisetsky
Desirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 12.350

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2018 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorial

- 1247** Bisphosphonates: a therapeutic option for knee osteoarthritis?
W F Lems

Views on news

- 1249** Role of Epstein-Barr virus infection in SLE: gene-environment interactions at the molecular level
D S Pisetsky

Recommendation

- 1251** 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis

A-K Rausch Osthoff, K Niedermann, J Braun, J Adams, N Brodin, H Dagfinrud, T Duruoz, B A Esbensen, K-P Günther, E Hurlmans, C B Juhl, N Kennedy, U Kiltz, K Knittle, M Nurmohamed, S Pais, G Severijns, T W Swinnen, I A Pitsillidou, L Warburton, Z Yankov, T P M Vliet Vlieland

Clinical and epidemiological research

- 1261** Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors

X M Teitsma, J W G Jacobs, P M J Welsing, P H P de Jong, J M W Hazes, A E A M Weel, A Pethö-Schramm, M E A Borm, J M van Laar, F P J G Lafeber, J W J Bijlsma

- 1268** Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)

Y Kaneko, M Kato, Y Tanaka, M Inoo, H Kobayashi-Haraoka, K Amano, M Miyata, Y Murakawa, H Yasuoka, S Hirata, E Tanaka, N Miyasaka, H Yamamata, K Yamamoto, T Takeuchi, the SURPRISE study group

- 1276** Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration
K Lauper, D C Nordström, K Pavelka, M V Hernández, T K Kvien, E K Kristianslund, M J Santos, Ž Rotar, F Iannone, C Codreanu, G Lukina, S L Gale, K Sarsour, Y Luder, D S Courvoisier, C Gabay

- 1283** The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: the STARTER study
G Filippou, G Sakellariou, C A Scirè, G Carrara, F Rumi, E Bellis, A Adinolfi, A Batticciotto, A Bortoluzzi, G Cagnotto, M Caprioli, M Canzoni, F P Cavatorta, O De Lucia, V Di Sabatino, A Draghessi, I Farina, M C Focherini, A Gabba, M Gutierrez, L Idolazzi, F Luccioli, P Macchioni, M S Massarotti, C Mastaglio, L Menza, M Muratore, S Parisi, V Picerno, M Piga, R Ramonda, B Raffener, D Rossi, S Rossi, P Rossini, C Scioscia, C Venditti, A Volpe, A Iagnocco

- 1290** Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls
B Michelsen, T Uhlig, J Sexton, D van der Heijde, H B Hammer, E K Kristianslund, A Wierød, G Bakland, E Rødevand, F Krøll, J H Loge, G Haugeberg, T K Kvien

- 1295** Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
D Baeten, M Østergaard, J C-C Wei, J Sieper, P Järvinen, L-S Tam, C Salvarani, T-H Kim, A Solinger, Y Datsenko, C Pamulapati, S Visvanathan, D B Hall, S Aslanyan, P Scholl, S J Padula

- 1303** Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study
S Rodrigues Manica, A Sepriano, S Ramiro, F Pimentel Santos, P Putrik, E Nikiphorou, S Norton, A Molto, M Dougados, D van der Heijde, R B M Landewé, F E van den Bosch, A Boonen

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

Member since 2008
JMS0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 1311** Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis

U Kiltz, D van der Heijde, A Boonen, N Akkoc, W Bautista-Molano, R Burgos-Vargas, J C-C Wei, P Chiowchanwisawakit, M Dougados, M T Duruoz, B K Elzorkany, I Gaydukova, L S Gensler, M Gilio, S Grazio, J Gu, R D Inman, T-J Kim, V Navarro-Compan, H Marzo-Ortega, S Ozgocmen, F P dos Santos, M Schirmer, S Stebbings, F E Van den Bosch, A van Tubergen, J Braun

- 1318** Changing patterns in clinical–histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis



G Moroni, P G Vercelloni, S Quaglini, M Gatto, D Gianfreda, L Sacchi, F Raffiotta, M Zen, G Costantini, M L Urban, F Pieruzzi, P Messa, A Vaglio, R A Sinico, A Doria

- 1326** Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model

W Wu, S Jordan, M O Becker, R Dobrota, B Maurer, H Fretheim, S Ye, E Siegert, Y Allano, A-M Hoffmann-Vold, O Distler

- 1333** Improved survival with renal transplantation for end-stage renal disease due to granulomatosis with polyangiitis: data from the United States Renal Data System

Z S Wallace, R Wallwork, Y Zhang, N Lu, F Cortazar, J L Niles, E Heher, J H Stone, H K Choi

- 1339** Urinary epidermal growth factor predicts renal prognosis in antineutrophil cytoplasmic antibody-associated vasculitis

L Wu, X-Q Li, T Goyal, S Eddy, M Kretzler, W-J Ju, M Chen, M-H Zhao

Basic and translational research

- 1345** Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis



A Sohrabian, L Mathsson-Alm, M Hansson, A Knight, J Lysholm, M Cornillet, K Skriver, G Serre, A Larsson, T Weitoft, J Rönnelid

- 1354** Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors

X Ma, S Nakayamada, S Kubo, K Sakata, K Yamagata, Y Miyazaki, M Yoshikawa, Y Kitanaga, M Zhang, Y Tanaka

- 1362** Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis



C P Denton, V H Ong, S Xu, H Chen-Harris, Z Modrusan, R Lafyatis, D Khanna, A Jahreis, J Siegel, T Sornasse

- 1372** Connective tissue growth factor contributes to joint homeostasis and osteoarthritis severity by controlling the matrix sequestration and activation of latent TGFβ



X Tang, H Muhammad, C McLean, J Miotla-Zarebska, J Fleming, A Didangelos, P Önnerrfjord, A Leask, J Saklatvala, T L Vincent

Letters

- 1381** European families reveal MHC class I and II associations with autoimmune-mediated congenital heart block

N C Kyriakidis, I Kockum, H Julkunen, A Hoxha, S Salomonsson, L Meneghel, C Ebbing, The Swedish Congenital Heart Block Study Group, A Dilthey, M Eronen, S D Carolis, T Kiserud, A Ruffatti, J Kere, S Meisgen, M Wahren-Herlenius

- 1382** Tracking digital ulcers in systemic sclerosis: a feasibility study assessing lesion area in patient-recorded smartphone photographs

G Dinsdale, T L Moore, J B Manning, A K Murray, R Atkinson, K Ousey, M R Dickinson, C Taylor, A L Herrick

- 1384** IgG4-related disease of the mitral valve demonstrated by immunohistochemistry

B K Tiong, G A Fishbein, E Brahn

- 1386** CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease



M Akiyama, H Yasuoka, K Yoshimoto, T Takeuchi

- 1387** Efficacy of infliximab in the treatment of Erdheim-Chester disease

F Cohen-Aubart, P Maksud, J-F Emile, N Benameur, F Charlotte, P Cluzel, Z Amoura, J Haroche

Electronic pages

- e56** Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis

T Morita, K Fujimoto, Y Shima, A Ogata, A Kumanogoh

- e57** Rheumatoid arthritis, γδ T cells and bisphosphonates

M Rossini, G Adami, O Viapiana, L Idolazzi, A Fassio, A Giollo, C Caimmi, G Orsolini, D Gatti

- e58** Amino-bisphosphonates, γδ T cells, and their roles in Rheumatoid Arthritis

W-X Mo, S-S Yin, H Chen, X Zhang

- e59** Metabolic and cardiovascular benefits of hydroxychloroquine: exploration in a wider population at high CV risk
A Pareek, I Purkait, R T Mehta, A Grover
- e60** Statins in systemic lupus erythematosus
C Abud-Mendoza
- e61** How useful is PET/CT in the evaluation of fever/inflammation of unknown origin? Comment on the article by Schönau *et al*
M Bredemeier
- e62** Uric acid and incident dementia: a population-based cohort study
Y H Lee, G G Song
- e63** Response to: 'Uric acid and incident dementia: a population-based cohort study' by Lee and Song
A Latourte, A Soumaré, T Bardin, S Debette, P Richette
- e64** Correction: *European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups*